Skip to main content
Clinical Trials/NL-OMON39784
NL-OMON39784
Completed
Not Applicable

Evaluation of Balloon-based Focal Cryoablation of Human Esophageal Epithelium - EBCA Focal

C2 Therapeutics0 sites29 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
esophageal cancer
Sponsor
C2 Therapeutics
Enrollment
29
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
C2 Therapeutics

Eligibility Criteria

Inclusion Criteria

  • a) Patients with known high grade dysplasia or early adenocarcinoma in BE.
  • b) Patients scheduled for ablation\- and/or EMR\-therapy gastroscopies, during which cryoablation may be performed.
  • c) Patient is 18 to 80 years of age at the time of consent (inclusive).
  • d) Patient has provided written Informed Consent (IC) using an Informed Consent Form (ICF) that has been approved by the Institution\*s reviewing IRB/EC.
  • e) Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
  • f) Patient is deemed operable per standard institutional criteria.
  • g) Each patient has a C\&M classification of C\*2 and/or M\*3\.
  • h) Each patient will have one area of BE or one island of BE \>1 cm2 where the Cryoballoon Focal Ablation System can be successfully positioned within the BE lesion. Cryoballoon ablation should be performed within 1 cm of the proximal border of the Barrett\*s epithelium.
  • i) BE lesion within the treatment zone should be flat.

Exclusion Criteria

  • a) Patient with endoscopically active inflammation in the treatment zone
  • b) Esophageal stenosis preventing advancement of a therapeutic endoscope and/or within 4 cm of treatment zone.
  • c) Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post treatment instructions or follow\-up guidelines.
  • d) Patient refuses or is unable to provide written informed consent.
  • e) Patients that received prior treatment with any energy\-based ablation system.
  • f) Endoscopically visible abnormalities such as masses or nodules within 4 cm of the treatment zone.

Outcomes

Primary Outcomes

Not specified

Similar Trials